Skip to main content
. 2022 Dec 23;13:1074857. doi: 10.3389/fneur.2022.1074857

Table 1.

Clinical characteristics of migraine patients at baseline.

Variables N (%) or (Mean ±SD)
Age (years) 35.20 ± 12.64
Gender Male 43 (31.9)
Female 92 (68.1)
NRS Mild (0~3) 52 (38.5)
Moderate(4~6) 70 (51.9)
Severe (7~10) 13 (9.62)
Pain sensation Persistent 21 (15.6)
Paroxysmal 6 (4.4)
Pulsatile 18 (13.3)
Splitting 4 (3.0)
Stabbing 3 (2.2)
Pain location Bilateral 54 (40.0)
Unilateral 81 (60.0)
Temporal 16 (11.9)
Occiput 59 (43.7)
Parietal 55 (40.7)
Frontal 47 (34.8)
Neck-Shoulder 30 (22.2)
Temple 61 (45.2)
Periocular 35 (25.9)
Tenderness Occiput 23 (17.0)
Temporal 23 (17.0)
Occipital nerve 21 (15.6)
Parapophyses of cervical 27 (20)
Trapezius 29 (21.5)
Sternocleidomastoid 1 (0.7)
Neck-Shoulder 15 (11.1)
Pain duration (years) 0~5 50 (37.0)
6~10 40 (29.6)
11~15 12 (8.9)
16~20 20 (14.8)
20~ 13 (9.6)
Duration of increased pain (months) 0~1 11 (8.1)
2~5 13 (9.6)
6~12 16 (11.9)
12~ 10 (7.4)
Pain frequency Once a month 23 (17.0)
Twice a month 57 (42.2)
Thrice a month 44 (32.6)
More than thrice a month 11 (8.1)
Family history for migraine 9 (6.7)
Analgesic drugs Tizanidine 105 (77.8)
Methylcobalamin 60 (44.4)
Folic acid 45 (33.3)
Qing Peng Ruan Gao 38 (28.1)
Du Liang Ruan Jiao Nang 37 (27.4)
Pregabalin 35 (25.9)
Acetaminophen 34 (25.2)
Eperisone 34 (25.2)
Calcitriol 30 (22.2)
Imrecoxib 26 (19.3)
Gu Tong Tie Gao 25 (18.5)
Gabapentin 24 (17.8)
Topiramate 19 (14.1)
Promethazine 16 (11.9)
Flunarizine 15 (11.1)
Lidocaine 14 (10.4)
Loxoprofen 13 (9.6)
Ropivacaine 12 (8.9)
Botulinum toxin 12 (8.9)
Vitamin B6 12 (8.9)
Bai Mai Ruan Gao 9 (6.7)
Tandospirone 8 (5.9)
Propacetamol 8 (5.9)
Celecoxib 7 (5.2)
Diclofenac diethylamine 7 (5.2)
Adenosylcobalamin 7 (5.2)